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Abstract
Background: Antidepressant use continues to rise, mainly explained by an increase in the proportion of patients
receiving long term treatment. Although treatment guidelines recommend discontinuation after sustained remission,
discontinuing antidepressants appears to be challenging for both patients and general practitioners (GPs). Mindfulness-
Based Cognitive Therapy (MBCT) is an effective intervention that reduces the risk of relapse in recurrent depression and
might facilitate discontinuation by teaching patients to cope with withdrawal symptoms and fear of relapse. The
current study aims to investigate the effectiveness of the combination of Supported Protocolized Discontinuation
(SPD) and MBCT in comparison with SPD alone in successful discontinuation of long-term use of antidepressants in
primary care.
Methods: This study involves a cluster-randomized controlled trial conducted in primary care patients with long-term
use antidepressants with baseline and 6, 9 and 12months follow-up assessments. Patients choosing to discontinue
their medication will be offered a combination of SPD and MBCT or SPD alone. Our primary outcome will be full
discontinuation of antidepressant medication (= 0 mg) within 6 months after baseline assessment. Secondary
outcome measures will be the severity of withdrawal symptoms, symptoms of depression and anxiety, psychological
well-being, quality of life and medical and societal costs.
Discussion: In theory, stopping antidepressant medication seems straightforward. In practice however, patients and
their GPs appear reluctant to initiate and accomplish this process. Both patients and professionals are in need of
appropriate tools and information to better support the process of discontinuing antidepressant medication.
Trial registration: ClinicalTrials.gov PRS ID: NCT03361514 retrospectively registered October 2017.
Keywords: Antidepressants, Discontinuation, Tapering, Long-term use, General practitioner, Primary health care,
Mindfulness-based cognitive therapy
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Background
Antidepressant use continues to rise. Between 2003 and
2013, antidepressant prescription numbers have doubled
in western countries [1], and have been rising with 3%
per year in the Netherlands [2]. Despite being effective
for some patients in reducing symptoms of depression
and anxiety and reducing the risk of depressive relapse
[3] antidepressants may also have side effects such as
sleep disturbance, weight gain, sexual dysfunction and
gastrointestinal bleeding [4, 5]. In addition, they some-
times even go along with more serious adverse events,
such as falls, attempted suicide or self harm, stroke and
epilepsy [6]. Consequently, current primary care guide-
lines advise to consider discontinuation of antidepres-
sants 6 months after remission of a depression or 6–12
months after remission of an anxiety disorder. Patients
with recurrent depression are advised to discontinue
medication after 1–2 years. It is generally recommended
to taper slowly, with guidelines suggesting a 50% dose
reduction every 2 weeks while monitoring side effects
and deploying relapse prevention strategies [7]. The pace
of tapering seems important as it appears to influence the
risk of relapse in patients with depressive disorder [8].
However, the steady rise of antidepressant use seems
to be explained mainly by an increase in long-term users
[9]. In the UK and US, 50–65% of patients treated with
antidepressants continue to use them for more than 2
years [10–12]. After starting antidepressant medication
almost 30% of the patients become chronic users, de-
fined as the consecutive use of any antidepressant for at
least 12 months [13]. Despite the general guidelines on
tapering antidepressants in primary care, actually dis-
cussing and initiating discontinuation appears to be
challenging [14, 15]. Stopping antidepressant medication
might be hampered by the presence of physical or psy-
chological withdrawal symptoms, including headache,
dizziness, electric-shock sensations, sleep disturbance,
anxiety and mood swings. These symptoms may easily
be misidentified as signs of impending relapse [16]. In
addition, earlier unsuccessful attempts to discontinue
may provoke further fears for withdrawal symptoms and
relapse. Previous research in a sample of 146 inappropri-
ate long-term antidepressant users from 45 general prac-
tices in the Netherlands showed that a multidisciplinary,
patient tailored advice to discontinue antidepressant
medication was rejected in 48% of the cases. The pro-
portion of successful antidepressant discontinuation fol-
lowing this multidisciplinary advice was only 6% [17].
To protect against depressive relapse after the acute
phase of depression several psychotherapeutic treatment
strategies have evolved [18]. This way alternatives for pa-
tients not wanting to maintain antidepressants seem
available. Mindfulness Based Cognitive Therapy (MBCT)
is one of these approaches of relapse prevention, it is an
innovative psychological approach for relapse/recurrence
prevention in recurrent depression developed by Segal,
Williams & Teasdale [19]. It is an 8-week group-based
treatment that integrates elements from mindfulness-
based stress reduction (MBSR) [20] and cognitive–be-
havioural therapy (CBT) [21]. A recent meta-analysis
showed that MBCT appears efficacious as a treatment
for relapse prevention for those with recurrent depres-
sion. MBCT reduces the risk of depressive relapse/recur-
rence compared with the current mainstay approach,
maintenance antidepressants [22]. As MBCT appears to
be a viable alternative to antidepressant medication it is
possible that mindfulness could provide patients support
in the de-identification of thoughts and allowing of un-
comfortable physical and mental symptoms, and also
help them to deal with possible withdrawal effects.
There is some evidence that MBCT might be useful in
supporting tapering of antidepressant medication. Two
randomized controlled trials in the UK, offering recur-
rently depressed patients MBCT with additional tapering
support, show successful tapering of Antidepressant
Medication (ADM) in 75% [23] and 71% of participants
[24]. However, results from a study conducted in the
Netherlands were less promising. Only 53% of the pa-
tients allocated to the group who received MBCT and
tapering support succeeded in tapering their antidepres-
sants [25]. Remarkably, there was a relatively large num-
ber of “cross-overs” in this trial, as 12% of patients who
were asked to continue their medication after MBCT ac-
tually discontinued their antidepressant medication suc-
cessfully. This latter trial showed that tapering was not
necessarily easy even after MBCT, but that the perspec-
tive of the patient (e.g. preferences, motives, previous ex-
periences with withdrawal) may have played a significant
role. The authors suggested that MBCT for tapering
ADM might need to be offered in homogeneous groups
of patients who are eager to withdraw from their
medication and that it should be specifically tailored
to address effects of discontinuation within the mind-
fulness framework.
Therefore, the aim of this study is to investigate the ef-
fectiveness of the combination of supported protocolized
discontinuation (SPD) and mindfulness-based cognitive
therapy (MBCT) in comparison with SPD alone in suc-
cessfully discontinuing long-term use of antidepressants
in primary care. SPD is carried out by the GP and
mental health assistant (MHA). The function of the
MHA (POH-GGZ in Dutch this is an abbreviation for
Practice Support Professional for Mental Health Care)
was installed in the Netherlands in 2008 to support
GPs in diagnosing, treating and referring patients with
mental health problems. In 2016 in the Netherlands
81% of all GP’s have arranged a MHA in their
practice.
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Our main hypothesis is that long-term users of antide-
pressants in primary care receiving SPD +MBCT will
more often successfully discontinue their medication
within a period of 6 months than patients receiving SPD
alone. Our secondary hypotheses are that, in comparison
with patients receiving SPD alone, patients who receive
SPD +MBCT will have a lower rate of relapse/recur-
rence of a depressive or anxiety disorder, a lower rate of
restarting medication, suffer less from withdrawal symp-
toms, report less depression, anxiety, and ruminative
brooding, and more mindfulness skills, self-compassion
and psychological wellbeing over the 12months follow-
up period.
Methods
Design
This study is designed as a cluster-randomized con-
trolled trial conducted in primary care with GP’s that
work with a MHA, randomizing patients at the level of
their GPs over a) Supported Protocolized Discontinuation
(SPD) alone or b) SPD with additional Mindfulness-Based
Cognitive Therapy (MBCT). We choose cluster random-
isation for practical reasons, i.e. to simplify the procedures
within the GP Practices. The patient, GP and the research
team will be aware of the allocated condition. However,
the mental health assistant MHA of the GP will be blind
to the condition as much as possible by asking the GP not
to inform the MHA about their allocated study arm. In
addition we will ask participants in the SPD +MBCT con-
dition to refrain from informing pro-actively about their
participation in the MBCT. Regarding recruitment a de-
tailed explanation is written in the Procedure. For a study
flowchart see Fig. 1. The study protocol has been ap-
proved by the Medical Ethics Committee Arnhem-Nij-
megen and registered under number 2016–2527.
Participants
Patients will be recruited from GPs with a mental health
assistant in the north, middle and east part of the
Netherlands and only included in the study after in-
formed consent has been obtained.
Inclusion criteria
In order to be eligible to participate in this study pa-
tients must have received prescriptions for antidepres-
sants in primary care for at least the past 9 months and
be 18 years or older.
Exclusion criteria
Patients who meet any of the following criteria will be
excluded from the study: current treatment by a psych-
iatrist; current substance use disorder; non-psychiatric
indication for long-term antidepressant usage (i.e. neuro-
pathic pain); having participated in a mindfulness training
(> 3 sessions) within the last 5 years; or inability to per-
form the assessments due to cognitive or language
difficulties.
Safety and monitoring
Patients will be free to increase the dosage or restart
their medication at any time during the study. In case of
difficulties during the discontinuation process patients
are advised to contact their GP and or MHA. Suspected
serious adverse events will be recorded and reported to
the Medical Ethics Committee Arnhem-Nijmegen.
Sample size
Based upon earlier research we expect a discontinuation
rate for patients in the SPD condition of 15% and a 40%
discontinuation rate for patients in the SPD +MBCT
condition. We used data from Eveleigh [17] to predict
discontinuation in the SPD condition (where 6% suc-
cessful discontinuation was observed according to very
strict criteria, and we made adaptations to align with the
context of the current setting, e.g. all patients had a clear
intention to taper). To estimate the rate in the SPD +
MBCT condition, we looked at studies with available
data on adherence to tapering after MBCT, ranging be-
tween 53 and 71% [23–25]. Again we made a conserva-
tive adaptation of 40% to account for differences in time
frame (6 versus 15months), intention-to-treat versus
per-protocol sample, and considering the difficulties in
discontinuation and withdrawal symptoms as mentioned
in the literature [16]. The following assumptions were
used in the sample size calculation: power 80%, alpha of
5% and two tailed testing. Due to the fact that the trial
will be cluster randomized, the calculated number of pa-
tients assuming individual randomization, has to be in-
flated by a design factor. To account for this an intra-
class correlation (ICC) of 0.05 was used, which is com-
monly used for research including outcome measures
[26]. With regard to the mentioned research we also as-
sume a dropout rate of 15%. Taking these figures into
account a total of 24 GPs have to be included, with 138
patients participating in the study; including 69 patients
per described condition; presenting an estimate of 5 par-
ticipating patients per GP.
Procedure
Eligible GPs will be informed about the study and re-
quested to participate. GP’s will be randomly allocated
to either SPD alone or SPD +MBCT. The GPs are asked
to identify patients using antidepressant medication for
more than 9months in their electronic prescription sys-
tem. Between 2016 and 2018 interested GP’s will invite
their long-term-users of ADM to discuss tapering via a
letter and return form. GPs are requested to inform the
research team about the number of patients who will
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not get an invitation including the reason(s).Patients’
reply forms will be collected by the research team and
interested patients will be invited to complete the online
screening questionnaire which includes demographic
characteristics, ADM-use, the Patient Health Question-
naire [27] and Generalized Anxiety Disorder [28]. Subse-
quently, they will receive an information brochure about
tapering, a decision aid and an invitation to make an
appointment with their GP. Patient and GP are en-
couraged to use the decision aid as a conversation
guideline to make a shared decision on whether or
not to discontinue the antidepressant medication.
After having consulted their GP about tapering and if
they decide to start tapering, patients will receive an
invitation to participate in the RCT and an invitation
for a research interview. During the interview written
informed consent that has been approved by the
Medical Ethics Committee of Arnhem-Nijmegen will
be obtained. The psychiatric structured diagnostic
interview that will be conducted [29] will take about
60–90 min altogether. Patients will also be requested
to complete baseline measures online. Thereafter pa-
tients will be advised to plan meetings with the Men-
tal Health Assistant for their SPD. Those patients
allocated to SPD +MBCT will be invited to partici-
pate in the first upcoming MBCT course. Follow up
measurements take place six, nine and 12 months
after baseline using telephone interviews and online
Fig. 1 Flow chart of the recruitment and study procedure
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questionnaires. The first assessment took place in
February 2017, the last assessment will take place in
July 2019.
Interventions
Supported Protocolized discontinuation (SPD)
Patients who choose to discontinue their medication will
make a personal tapering schedule with their GP based
upon a discontinuation protocol with tapering sugges-
tions. The protocol offers suggestions to taper within a
maximum of 6 months describing all types of available
dosages per ADM so individualized schedules can be
constructed. The protocol is available upon request
through the research team (CW). In addition, they will
be offered supportive meetings with the GP’s mental
health assistant. The assistant will receive basic informa-
tion about discontinuation guidance, i.e. the information
brochure, decision aid, discontinuation protocol and a
short guideline how to organise consultations. The short
guideline is available upon request through the research
team (CW). Patients will be advised to discontinue their
medication within 6 months.
Mindfulness based cognitive therapy (MBCT)
MBCT will be offered according to the treatment proto-
col developed for recurrent depression [30], adapted to
the specific needs of patients discontinuing their anti-
depressant medication. The psycho-education sections
about depression will be extended with information
about pro and cons of stopping antidepressants, with-
drawal effects and anticipatory anxiety. Based on our ex-
pectation that the discontinuation process may take
longer than is currently regarded as common practice,
sessions 1–4 will take place on a weekly and sessions 5–
8 on a fortnightly basis. Each session will last 2.5 h with
a 6-h silent day between session six and seven. In
addition to the group sessions, participants will be
instructed to practice mindfulness for approximately 30
min a day. Participants will receive a digital link to
download guided meditations and yoga exercises for
home practice. The mindfulness courses will be provided
by teachers qualifying the advanced criteria of the Asso-
ciation of Mindfulness Based Teachers in the
Netherlands and Flanders, which include a) relevant pro-
fessional training; b) having attended MBSR / MBCT as
a participant; c) a minimum of 150 h of education in
MBSR/MBCT background and theory, training in teach-
ing formal and informal meditation practices, psycho-
education and inquiry, supervision and teaching an
MBSR or MBCT course including a reflection report; d)
teaching a minimum of two courses per 2 year; e) mini-
mum of 3 years of practicing meditation regularly and
attending retreats; and f) continued training. All
teachers will receive additional training in using the
specific study protocol at the start of the project. We
will organize two peer supervision meeting per course
during the intervention phase of the trial. Teaching ses-
sions will be videotaped to check treatment integrity. A
random selection of two tapes per teacher will be rated
for treatment adherence and competency by highly ex-
perienced MBCT/MBSR teachers with the Mindfulness-
Based Cognitive Therapy Adherence Scale [31].
Outcome measures
Table 1 presents an overview of the outcome measures
and the time points of assessments.
Primary outcome measure
Our primary outcome will be full discontinuation of
antidepressant medication (= 0 mg) within 6months
after starting the intervention. Use of medication will be
measured with daily calendars. Patients will be invited to
fill out paper calendars describing their type of anti-
depressant, daily milligrams used and consultations to
GP or mental health assistant regarding tapering. In case
of missing data in the reports, the GP will be contacted
to check the GP prescription database. This latter solu-
tion is considered reliable as in the Netherlands all pa-
tients are linked to only one GP who collects all medical
information for a particular patient.
Secondary outcome measure
– Relapse/recurrence in depression and/or anxiety will
be measured by the modules ‘screening, mood
episodes & disorders and anxiety disorders’ of the
Structural Clinical Interview for DSM-IV Axis I
Disorders (SCID-I), as the SCID-I for DSM-V was
not available at the start of the project. Interviews
will be conducted by qualified research assistants
who received one full day of training to use the
SCID-I. Interviews will be audio taped to allow
second-rating by an independent and blind assessor
in a random sample of tapes in order to prevent
bias. Previous studies on inter-rater reliability of the
SCID-I have reported Cronbach’s alpha values
between 0.61 and 0.80 [32]
– Withdrawal symptoms will be assessed by means of
the Discontinuation-Emergent Signs and Symptoms,
DESS. This self-report will be administered to all
patients using either SSRI, SNRI, TCA or other
antidepressant medication. The checklist consists of
43 items and is based on an evaluation of signs and
symptoms associated with discontinuation or
interruption of SSRI treatment, as reported in the
available literature [33]. A Dutch translation of
DESS by Grootheest will be used.
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– Depressive symptoms will be measured by the
Inventory for Depressive Symptoms, IDS-C. The 30-
item interview is designed to assess the severity of
depressive symptoms. In this study we use the
clinician rated version. The IDS-C has good
psychometric qualities [34, 35].
– Suicide cognitions will be measured by the module
Suicide Cognitions of the Mini International
Neuropsychiatric Interview, MINI. The 6-item
interview is designed to assess suicidal cognitions
over the last month and to specify suicidal risk. In
this study we use the clinician rated version [36].
– Anxiety symptoms will be measured by the State-Trait
Anxiety Inventory, STAI [37]. A self-report measure
which has been proven reliable and sensitive in the
assessment of both state and trait levels of anxiety. It is
a standard international measure in anxiety research
and its Dutch translation has been validated [38].
– Ruminative Brooding will be measured by the
brooding subscale of the extended version of the
Ruminative Response Scale (RRS-EXT) which
consists of 5 items. The authors reported adequate
internal consistency α = .79 and test–retest stability
(α = .62, 1 year time interval) [39].
– Positive mental health will be assessed with the 14-
item Dutch short-form version of the Mental Health
Continuum, MHC-SF [40]. The self-report
questionnaire assesses emotional, psychological and
social well-being. It has adequate psychometric
qualities in terms of good internal consistency,
(moderate) test-retest reliability, and good divergent
and convergent validity.
– Mindfulness skills will be assessed with the Dutch
short form of the Five Facet Mindfulness Questionnaire,
FFMQ-SF [41]. This is a self-report inventory that
specifies five mindfulness skills: observing, describing,
acting with awareness, non-judging and non-reactivity.
It consists of 24 items. The FFMQ has demonstrated to
be a reliable and valid measure in assessing mindfulness
in people with depressive symptoms.
– Self-compassion will be measured with the 12-item
Dutch short-form version of the Self-Compassion
Scale, SCS-SF [42]. The scale consists of six
components: self-kindness, self-judgment, common
humanity, isolation, mindfulness and over-identification.
The SCS-SF has good reliability and validity.
Cost-effectiveness
– Resource use such as use of care, medication and
illness related to work will be measured by means of
the TIC-P. The TIC-P is a self-report inventory that
consists of 38 items and measures both direct costs,
i.e. care consumption of people suffering from
psychiatric illness, and indirect costs, i.e. costs
associated with production loss over the 12 month
follow up period [43].
– To evaluate quality of life the EuroQol-5D, self-report
version, will be used [44]. The EQ-5D uses a
descriptive system of health-related quality of life states
consisting of five dimensions (mobility, self-care, usual
activities, pain/discomfort and anxiety/depression) each
of which can take one of three responses. In addition it
contains a visual analogue scale to determine Quality
Adjusted Life years (QALYs). The Dutch translation
will be used.
Randomization and statistical analysis
To prevent a crossover effect between the interventions,
cluster-randomization will be performed with the GP as
Table 1 Overview of the measures and corresponding time points
Measure Target concept Baseline (T0) FU6 months (T1) FU9 months (T2) FU12 months (T3)
Daily calendar Use of antidepressants Daily registration during 12 months
SCID I modules* Global psychopathology * * * *
DESS Discontinuation symptoms * * * *
IDS-C Depressive symptoms * * * *
STAI Anxiety trait & state * * * *
M.I.N.I. plus Suicidal Suicide cognitions * * * *
RRS-brooding Rumination brooding * * * *
MHC-SF Positive mental health * * * *
FFMQ-SF Mindfulness skills * * * *
SCS-SF Self compassion * * * *
TIC-P Direct and indirect costs * * * *
EQ-5D Quality of life * * * *
Note. *Scid I modules screening, mood episodes & disorders and anxiety disorders. All questionnaires are online self-reports except SCID-I modules and IDS-C
(interview) and daily calendar (pen&paper). If participants do not have internet-access paper questionnaires will be offered
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the unit of clustering. A senior academic statistician will
produce the randomization schedule based on a strati-
fied block randomization. Stratification variables consist
of region (north, central and east Netherlands) and type
of practice (single versus group practice). This schedule
will be send in a protected Excel-sheet to a research as-
sistant who will allocate the GP in order of their entry to
either intervention or control group. The research assist-
ant will communicate the allocation to the researcher
who will, in turn, communicate this to the GP. We are
not able to keep the SCID interviewer blind to the pa-
tient’s condition. The clinical outcome data will be
analysed and reported according to the CONSORT
guidelines, i.e. both on an intention-to-treat and per
protocol basis. With regard to missing data, sensitivity
analyses will be conducted with different types of imput-
ation. Multilevel analyses will be used to account for the
hierarchical structure of the data (i.e. multiple assess-
ments nested within patients, patients nested within
GPs, and GPs nested within practices).
Primary analysis
The primary analysis is aimed at comparing the effects
of SPD and SPD +MBCT with regard to the proportion
of patients who fully discontinue their antidepressant
medication within 6 months. Full discontinuation is de-
fined as using 0 mg antidepressant medication before or
at the 6-month assessment. Patients who drop out be-
fore this assessment will be classified as ‘not able to dis-
continue’ (for the primary outcome variable). However
sensitivity analyses will be conducted to examine dif-
ferent types of imputation. We will use a multilevel
logistic regression model for repeated measures to
analyze differences between the two conditions on
baseline, 6 months, 9 months and 12 months follow-up
measurements.
Secondary analyses
We will use Cox regression analysis for differences in
time to relapse/recurrence in depression and/or anxiety
and multilevel regression analysis for all other secondary
outcomes. Baseline scores of all continuous variables will
be included as covariates in the respective analyses.
Cost-effectiveness evaluation
The cost-effectiveness evaluation will be carried out
from both a medical and societal perspective considering
direct health related costs and societal costs following
the Dutch guideline [45]. Total costs, measured with the
TIC-P, will be estimated using an incremental bottom-
up (micro-costing) approach, where information on each
element of service used is multiplied by an appropriate
unit cost and summed to provide an overall total cost
[46]. We will consider four types of costs: (1)
intervention costs of offering the MBCT, (2) costs stem-
ming from health care uptake related to discontinuation,
(3) patients’ and their family’s out-of-pocket costs, (4)
costs stemming from productivity losses due to absen-
teeism related to discontinuation. The recall period will
be 4 weeks at baseline, and will consist of the entire
period between each of the follow-up assessments. Inter-
vention costs will include all the costs that will contrib-
ute to the development and administration of the
MBCT, for example costs of training and travel ex-
penses. Total costs for each patient will be obtained by
multiplying these data with standard costs, based on the
Dutch guideline for costing research [45]. Cost as out-
come are mostly skewed. In our analysis we will take
skewness into account by using a GLM approach with a
gamma distribution and log link. Cluster effects will be
accounted for by cluster robust standard errors. Descrip-
tive statistics on costs will be presented as well. Health-
related quality of life from baseline up to 12months will
be used to calculate QALYs based on the EQ-5D using
the trapezium rule. Incremental cost-effectiveness will
be expressed in terms of incremental costs per QALY
gained. Bootstrap simulations with 1,000 replications will
be used to produce uncertainty intervals in our eco-
nomic evaluation, taking into account the correlations
between costs and QALYs. A cost-effectiveness accept-
ability curve (CEAC) will be produced to show the prob-
abilities that either of the tested strategies is the cost-
effective option, given certain values for the cost-effect-
iveness threshold (i.e. a willingness to pay for a QALY
gained). If there are baseline differences between groups
a net monetary benefit and regression based framework
will be used. Uncertainty surrounding non stochastic pa-
rameters (like prices) will be explored using one way
sensitivity analyses.
Qualitative evaluation
In addition to the quantitative analysis, we also aim to
conduct a qualitative study according to Consolidated
criteria for reporting qualitative research, COREQ [47] .
We will conduct one-on-one, in-depth interviews with a
purposive sample of patients willing to discontinue their
antidepressant medication about barriers and facilitators
of this process.
Discussion
Both patients and professionals seem to call for appro-
priate tools and information to better support the
process of discontinuing antidepressant medication. In
the current study we will address this gap by devising a
protocol for shared decision making and the accompany-
ing materials (i.e. information brochure, decision aid,
and tapering protocol). This may serve a structured and
comprehensive way to approach discontinuation.
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One of the strengths of this study is its inclusive sam-
pling strategy, allowing all patients with long-term ADM
use to consider tapering and participation. Rather than a
priori precluding patients with a certain level of symp-
tomatology, for example with depressive or anxiety dis-
order, we used a shared decision making approach
(including topics related to psychological functioning
and effectiveness of antidepressant medication) to define
the final RCT population. The decision to taper an anti-
depressant seems multifaceted, and probably does not
solely depend on the level of symptoms. Another advan-
tage of this strategy is that rather than tapering, patients
and their GPs might consider switching to a different
medication if that seems more appropriate.
In addition this will be the first study that will directly
compare MBCT to facilitate discontinuation as an add-
on to support in general practice, with support alone.
This study will provide more information about the en-
tire process of discontinuation of antidepressants in a
population of long-term users in general practices, in-
cluding the views and preferences of GPs and patients
with regard to discontinuation, the value of using psy-
cho-education material about tapering, and the possible
value of MBCT to support the process.
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